fludarabine has been researched along with Aging in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aldridge, J; Alyea, EP; Antin, JH; Armand, P; Cutler, C; Ho, VT; Kim, HT; Koreth, J; Ritz, J; Soiffer, RJ | 1 |
| Asaka, M; Endo, T; Hashino, S; Imamura, M; Ito, YM; Kahata, K; Koike, T; Kondo, T; Nishio, M; Okada, K; Onozawa, M; Shigematsu, A; Sugita, J; Takahata, M; Tanaka, J; Yamamoto, S | 1 |
| Elliott, B; Grosskreutz, C; Isola, L; Malone, A; Mandeli, J; Osman, K; Scigliano, E | 1 |
| Appelbaum, FR; Belch, AR; Byrd, JC; Geyer, S; Kolitz, J; Larson, RA; Lin, TS; Morrison, VA; Rai, K; Ruppert, AS; Tallman, MS; Woyach, JA | 1 |
| De Braekeleer, M; Herry, A; Le Bris, MJ; Morel, F; Morice, P | 1 |
| Alinari, L; Baccarani, M; Bonifazi, F; Gentilini, P; Guardigni, L; Martelli, M; Molinari, AL; Perrotti, A; Pileri, S; Pulsoni, A; Stefoni, V; Tani, M; Tura, S; Villivà, N; Visani, G; Zinzani, PL | 1 |
| Januszewicz, EH; Milner, A; Polizzotto, MN; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM | 1 |
1 review(s) available for fludarabine and Aging
| Article | Year |
|---|---|
Trisomy 15 as the sole abnormality in myelodysplastic syndromes: case report and review of the literature.
Topics: Aging; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 15; Chromosomes, Human, Y; Clone Cells; Cyclophosphamide; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pancytopenia; Trisomy; Tumor Cells, Cultured; Vidarabine | 2003 |
1 trial(s) available for fludarabine and Aging
| Article | Year |
|---|---|
Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aging; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Treatment Outcome; Vidarabine | 2004 |
5 other study(ies) available for fludarabine and Aging
| Article | Year |
|---|---|
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.
Topics: Age Factors; Aged; Aging; Blood Donors; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Risk; Survival Analysis; Transplantation Conditioning; Transplantation Immunology; Treatment Outcome; Vidarabine | 2010 |
Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients.
Topics: Adult; Aged; Aging; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Myeloablative Agonists; Retrospective Studies; Risk Factors; Severity of Illness Index; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2010 |
Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma.
Topics: Adult; Aged; Aging; Antilymphocyte Serum; beta 2-Microglobulin; Cohort Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2010 |
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Immunotherapy; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Randomized Controlled Trials as Topic; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2013 |
The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Risk Factors; Rituximab; Vidarabine | 2006 |